BioSpace1h
While Lilly Blames Wholesalers for Slow GLP-1 Sales, Novo’s Rival Medicine Is Flowing
Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
Even with this partial rebound, Lilly's share price remains roughly 13% below the peak set in late August. Some investors ...
How does Viking's weight loss med compare to ones from Novo, Eli Lilly?
Data reported earlier Monday from Viking Therapeutics (NASDAQ:VKTX) on its weight loss medicine VK2735 indicates that Novo ...
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
salisburypost12h
RCCC benefits from involvement with Eli Lilly and Company’s Global Day of Service
RCCC News Service SALISBURY — Rowan-Cabarrus Community College and its students recently benefited from involvement with Eli Lilly and Company and its annual Global Day of Service. Student ...
Eli Lilly grows Milwaukee-area footprint with $40.8M warehouse acquisition — and more
Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
The Associated Press - Business News on MSN8d
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
Are Eli Lilly's Lowered Expectations a Reason to Sell?
Eli Lilly reported third-quarter results before the market opened on Wednesday. Management missed Wall Street estimates and lowered earnings guidance for 2024. Sales of Zepbound and Mounjaro ...
Is Eli Lilly Stock a Buy?
However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...